Tau immunotherapies for Alzheimer’s disease

Justin L. Hoskin, Marwan Noel Sabbagh, Yazan Al-Hasan, Boris DeCourt

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: Alzheimer’s dementia (AD) is the most common form of dementia in the World. Pathologically, it is characterized by extracellular β-amyloid plaques and intraneuronal neurofibrillary tangles (NFTs). The latter is composed of irregular, pathological forms of the tau protein. Currently, FDA-approved symptomatic treatments are limited to the targeting of cholinergic deficits and glutamatergic dysfunctions. However, as understanding of β-amyloid plaques and NFTs expands, these dysfunctional proteins represent potential therapeutic interventions. The present review article evaluates active and passive immunotherapies in clinical development for AD to date and their potential to significantly improve the treatment of AD going forward. Areas covered: All clinical trials that have targeted β-amyloid to date have produced somewhat disappointing results, leading to a shift in intervention focus to targeting tau protein. A key component in understanding the value of targeting tau in therapeutic paradigms has come from the conceptualization of prion-like pathological spread of tau isoforms from neuron to neuron, and referred to as ‘tauons’. Immunotherapies currently under investigation include approaches aiming at preventing pathological tau aggregation, stabilizing microtubules, and blocking of tauons. Expert opinion: A multi-targeted approach that would use biologics targeting tau offers great promise to the development of effective AD therapeutic interventions.

Original languageEnglish (US)
Pages (from-to)545-554
Number of pages10
JournalExpert Opinion on Investigational Drugs
Volume28
Issue number6
DOIs
StatePublished - Jun 3 2019
Externally publishedYes

Fingerprint

Immunotherapy
Alzheimer Disease
tau Proteins
Neurofibrillary Tangles
Amyloid Plaques
Therapeutics
Neurons
Active Immunotherapy
Passive Immunization
Prions
Expert Testimony
Biological Products
Amyloid
Microtubules
Cholinergic Agents
Dementia
Protein Isoforms
Clinical Trials
Proteins

Keywords

  • Alzheimer’s disease
  • clinical trials
  • monoclonal antibodies
  • passive immunotherapy
  • Tau

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Hoskin, J. L., Sabbagh, M. N., Al-Hasan, Y., & DeCourt, B. (2019). Tau immunotherapies for Alzheimer’s disease. Expert Opinion on Investigational Drugs, 28(6), 545-554. https://doi.org/10.1080/13543784.2019.1619694

Tau immunotherapies for Alzheimer’s disease. / Hoskin, Justin L.; Sabbagh, Marwan Noel; Al-Hasan, Yazan; DeCourt, Boris.

In: Expert Opinion on Investigational Drugs, Vol. 28, No. 6, 03.06.2019, p. 545-554.

Research output: Contribution to journalArticle

Hoskin, JL, Sabbagh, MN, Al-Hasan, Y & DeCourt, B 2019, 'Tau immunotherapies for Alzheimer’s disease', Expert Opinion on Investigational Drugs, vol. 28, no. 6, pp. 545-554. https://doi.org/10.1080/13543784.2019.1619694
Hoskin, Justin L. ; Sabbagh, Marwan Noel ; Al-Hasan, Yazan ; DeCourt, Boris. / Tau immunotherapies for Alzheimer’s disease. In: Expert Opinion on Investigational Drugs. 2019 ; Vol. 28, No. 6. pp. 545-554.
@article{5d8ed1a0df5a4113a80c1a2329829089,
title = "Tau immunotherapies for Alzheimer’s disease",
abstract = "Introduction: Alzheimer’s dementia (AD) is the most common form of dementia in the World. Pathologically, it is characterized by extracellular β-amyloid plaques and intraneuronal neurofibrillary tangles (NFTs). The latter is composed of irregular, pathological forms of the tau protein. Currently, FDA-approved symptomatic treatments are limited to the targeting of cholinergic deficits and glutamatergic dysfunctions. However, as understanding of β-amyloid plaques and NFTs expands, these dysfunctional proteins represent potential therapeutic interventions. The present review article evaluates active and passive immunotherapies in clinical development for AD to date and their potential to significantly improve the treatment of AD going forward. Areas covered: All clinical trials that have targeted β-amyloid to date have produced somewhat disappointing results, leading to a shift in intervention focus to targeting tau protein. A key component in understanding the value of targeting tau in therapeutic paradigms has come from the conceptualization of prion-like pathological spread of tau isoforms from neuron to neuron, and referred to as ‘tauons’. Immunotherapies currently under investigation include approaches aiming at preventing pathological tau aggregation, stabilizing microtubules, and blocking of tauons. Expert opinion: A multi-targeted approach that would use biologics targeting tau offers great promise to the development of effective AD therapeutic interventions.",
keywords = "Alzheimer’s disease, clinical trials, monoclonal antibodies, passive immunotherapy, Tau",
author = "Hoskin, {Justin L.} and Sabbagh, {Marwan Noel} and Yazan Al-Hasan and Boris DeCourt",
year = "2019",
month = "6",
day = "3",
doi = "10.1080/13543784.2019.1619694",
language = "English (US)",
volume = "28",
pages = "545--554",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Tau immunotherapies for Alzheimer’s disease

AU - Hoskin, Justin L.

AU - Sabbagh, Marwan Noel

AU - Al-Hasan, Yazan

AU - DeCourt, Boris

PY - 2019/6/3

Y1 - 2019/6/3

N2 - Introduction: Alzheimer’s dementia (AD) is the most common form of dementia in the World. Pathologically, it is characterized by extracellular β-amyloid plaques and intraneuronal neurofibrillary tangles (NFTs). The latter is composed of irregular, pathological forms of the tau protein. Currently, FDA-approved symptomatic treatments are limited to the targeting of cholinergic deficits and glutamatergic dysfunctions. However, as understanding of β-amyloid plaques and NFTs expands, these dysfunctional proteins represent potential therapeutic interventions. The present review article evaluates active and passive immunotherapies in clinical development for AD to date and their potential to significantly improve the treatment of AD going forward. Areas covered: All clinical trials that have targeted β-amyloid to date have produced somewhat disappointing results, leading to a shift in intervention focus to targeting tau protein. A key component in understanding the value of targeting tau in therapeutic paradigms has come from the conceptualization of prion-like pathological spread of tau isoforms from neuron to neuron, and referred to as ‘tauons’. Immunotherapies currently under investigation include approaches aiming at preventing pathological tau aggregation, stabilizing microtubules, and blocking of tauons. Expert opinion: A multi-targeted approach that would use biologics targeting tau offers great promise to the development of effective AD therapeutic interventions.

AB - Introduction: Alzheimer’s dementia (AD) is the most common form of dementia in the World. Pathologically, it is characterized by extracellular β-amyloid plaques and intraneuronal neurofibrillary tangles (NFTs). The latter is composed of irregular, pathological forms of the tau protein. Currently, FDA-approved symptomatic treatments are limited to the targeting of cholinergic deficits and glutamatergic dysfunctions. However, as understanding of β-amyloid plaques and NFTs expands, these dysfunctional proteins represent potential therapeutic interventions. The present review article evaluates active and passive immunotherapies in clinical development for AD to date and their potential to significantly improve the treatment of AD going forward. Areas covered: All clinical trials that have targeted β-amyloid to date have produced somewhat disappointing results, leading to a shift in intervention focus to targeting tau protein. A key component in understanding the value of targeting tau in therapeutic paradigms has come from the conceptualization of prion-like pathological spread of tau isoforms from neuron to neuron, and referred to as ‘tauons’. Immunotherapies currently under investigation include approaches aiming at preventing pathological tau aggregation, stabilizing microtubules, and blocking of tauons. Expert opinion: A multi-targeted approach that would use biologics targeting tau offers great promise to the development of effective AD therapeutic interventions.

KW - Alzheimer’s disease

KW - clinical trials

KW - monoclonal antibodies

KW - passive immunotherapy

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=85066839173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066839173&partnerID=8YFLogxK

U2 - 10.1080/13543784.2019.1619694

DO - 10.1080/13543784.2019.1619694

M3 - Article

C2 - 31094578

AN - SCOPUS:85066839173

VL - 28

SP - 545

EP - 554

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 6

ER -